Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi-Pasteur promotes Olivier Charmeil

This article was originally published in Scrip

Executive Summary

Sanofi-Aventis has appointed Olivier Charmeil senior vice-president of its vaccines division, Sanofi Pasteur. Mr Charmeil succeeds Wayne Pisano, who will retire in February 2011. Mr Charmeil, who is currently senior vice-president of global operations Asia/Pacific and Japan, will report directly to Christopher Viehbacher, Sanofi-Aventis's CEO, and will become a member of the executive committee. Mr Charmeil joined Sanofi Pharma in 1994 as head of business development and has held a number of key positions since then, including CFO Asia and CEO of the French affiliate, taking up his current role in February 2006. Prior to joining Sanofi Pharma, Mr Charmeil was a banker focusing on mergers and acquisitions at Banque de l’Union Européenne.

You may also be interested in...

AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments

Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.

Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies

Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.

Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options

Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts